U.S. Markets closed

Cell MedX Corp. Announces First Subjects Screened and Qualified for the Observational Clinical Trial

CARSON CITY, NV / ACCESSWIRE / March 9, 2017 / Cell MedX Corp. (CMXC), ("Cell MedX" or the "Company"), is pleased to announce that Dr. Richard Tytus, the Lead Investigator on the previously announced Observational Clinical Trial (the "Trial"), and his team at Hamilton Medical Research Group have commenced screening for qualified subjects.

The group of seven potential study participants have been screened with an additional five subjects scheduled for screening. Three subjects have qualified for participation in the study and two more are pending qualification based on receipt of their bloodwork. It is expected that additional subjects will be enrolled over the next two weeks.

The intent of this Observational Clinical Trial is to assess the impact of three months of eBalance therapy as an adjunct treatment, on HbA1c in Type 1 and Type 2 diabetics. The secondary endpoints of the Trial will observe changes from baseline and medical history in the following;

  • Insulin sensitivity
  • Diabetic neuropathy
  • Diabetic foot pain and numbness
  • Wound healing
  • Blood pressure
  • Kidney function
  • To take into account any other changes reported by patients

The Trial is being conducted over a four to six month period enrolling a minimum of 30 individuals who will receive three months of eBalance therapy. All study participants will be screened to confirm a diagnosis of either Type 1 or Type 2 diabetes.

Mr. McEnulty, the Company's CEO, stated: "I am very excited to get these Observational Clinical Trials underway and am looking forward to what we at Cell MedX believe will be encouraging results."

About Cell MedX Corp.

Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, high blood pressure. For more information about the Company and its technology please visit our website at: www.cellmedx.com, for the Company's newsletter, please go to www.cellmedx.com/media/newsletters/

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty
Chief Executive Officer and President.

Forward Looking Statements

The information included in this press release has not been reviewed by the FDA, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

For further information visit: www.cellmedx.com
Or phone: 1-844-238-2692

SOURCE: Cell MedX Corp.